Bioasis Technologies Inc. V.BTI

The recent Option Grant.

[narmac]

Latest 10 SEDI filings for BTI within the last 6 months

View on INK Research

 Amended Filing

As of 11:59pm ET August 12th, 2022

Filing Date	Transaction Date	Insider Name	Ownership Type	Securities	Nature of transaction	Volume or Value	Price
Aug 9/22	Aug 8/22	Rathjen, Deborah Ann	Direct Ownership	Options	50 - Grant of options	584,000
Aug 9/22	Aug 8/22	Wurzer, David M.	Direct Ownership	Options	50 - Grant of options	262,000
Aug 9/22	Aug 8/22	Curran, John	Direct Ownership	Options	50 - Grant of options	262,000
Aug 9/22	Aug 8/22	Saltarelli, Mario David	Direct Ownership	Options	50 - Grant of options	262,000
Aug 9/22	Aug 8/22	Hemeon, John M.	Direct Ownership	Options	50 - Grant of options	262,000
Aug 9/22	Aug 8/22	Jenkins, David P	Direct Ownership	Options	50 - Grant of options	146,000
Apr 29/22	Apr 21/22	Hemeon, John M.	Direct Ownership	Warrants	55 - Expiration of warrants	-250,000

[prophetoffactz]

It's been two weeks since the financial statements were released with an immediate need for cash. You would think a competent management would have announced a small financing by now if that was the path forward. There are only 13 trading days left in the month and until BTI's cash runs out. The current price is a disaster for raising money given the dilution; however, they didn't

[JDavenport]

Some of the long-time board members have options that are in their late fourth, perhaps even in their fifth year, meaning that these options are getting close to expiring. (Somebody else can look up the expiry dates.) The new options are likely intended to replace those options, as well as to position others who should have some options. (I don't know how or why a contracted IR consultant can

[prophetoffactz]

If BTI is going to give away shares in a financing at this price it could do a $2.5 million financing at $.15 with a full one year warrant at $.50 with an acceleration clause. Then it could release the news and soon potentially have $10.5 million from this financing alone effectively at $.325.  

[JDavenport]

Yeah but, xB3-001 may turn out to be the easiest and quickest blockbuster drug ever brought to market and if Bioasis sells it off to a currently unidentified allied entity, then it could bring in tens of millions up front and financing days would be over except as strategic positioning, as with a NASDAQ listing. And the real purpose of a financing may as be much to make friends happy as for

[prophetoffactz]

Hard to imagine issuing all those $.13 options if you are working on and about to announce a major deal. Denali is up about 80% in less than two months and that was a company BTI compared itself to.

[JDavenport]

Are you kidding, pof? Now is the time to issue cheap options. Insiders know the story. They know what's coming. It's meaningful when they issue options to themselves, however shamelessly they set the price.   These options, exercisable at 13¢, might as well have been given to the insiders for nothing because Bioasis does compare with Denali, and investors should see a share

[KayakerBC]

Yeah but, xB3-001 may turn out to be the easiest and quickest blockbuster drug ever brought to market and if Bioasis sells it off to a currently unidentified allied entity, then it could bring in tens of millions up front and financing days would be over except as strategic positioning, as with a NASDAQ listing. Tens of millions.  Wouldn't that be nice.  Extremely unlikely but that&

[JDavenport]

I can't be bothered arguing, but AstraZeneca paid just under $1.35 billion up front and agreed to pay contingent payments of up to $5.5 billion for a trastuzumab drug (Enhertu) that will not be a competitor to Bioasis's xB3-001. That's a total of almost $7 billion for Enhertu. If Bioasis got only $135 million up front and another $550 million in milestones, that is still only 10% of

[prophetoffactz]

The key is that BTI has more than one party interested in the xB3 cancer assets, it appears. That can lead to a bidding war that helps secure a more efficient price. More than just the xB3 Herceptin asset may also be at stake. BTI appears interested in a broader deal for its cancer assets and has done work beyond Herceptin. BTI has narrowed its own focus outside of cancer. Daiichi has been spotted

[JDavenport]

Let's state it all in a very simple way, pof.  I think it likely that Bioasis is down to one company for xB3-001 and possibly for the other xB3 cancer drugs. I think it possible that an announcement of such, and announcements relating to xB3-004, xB3-progranulin and other licensing and partnership agreements, will be revealed in the weeks and months ahead. I believe the execution of this

[KayakerBC]

more than one party interested in the xB3 cancer assets....bidding war.... world class companies....xB3 validation....potential bidding war....world class interest....potential substantial deal.... POOF!  Bravo!  As your pumper posts go, this one is in a whole different league!  However, you forgot to mention the part where Bioasis cures COVID and wins the war in Ukraine and pushes

[KayakerBC]

Last week, you put up a lengthy post which prompted the usual unhelpful one-liner from BeenThere.  To which you reasonably responded.... Make your case. Make an argument. Make an argument, beenthere. Otherwise all you've got is mindless blah blah blah. Now here is somebody (me) posting a contrary argument and your response is: "I can't be bothered arguing....". Reduce

[JDavenport]

With the greatest of respect, KBC, let me respond. Now here is somebody (me) posting a contrary argument and your response is: "I can't be bothered arguing....". I have been presenting information and making argument for over ten years. I'm still doing it. If I choose to summarize all of that because I don't want to write it out for the 500th time then I think I've

[KayakerBC]

....anything in the low tens of millions up front and mid hundreds of millions in milestones will be a disappointment.... Realistically, I think even that's high.  Waaaaay high on the up front $$$. And as I said in my last post..... ....if there will be an XB3-001 upfront payment anything remotely like what you expect, why is the current plan to pay for the upcoming Phase II study

[JDavenport]

KBC asked, "...why is the current plan to pay for the upcoming Phase II study -- right before the NASDAQ listing -- with a financing?  Why won't we have more than sufficient cash to fund it?...." Now, there be several interesting questions in there. I don't think a NASDAQ listing can happen until Q2 or Q3 of 2023. There's just too much to do. I think a financing is

[KayakerBC]

I think a financing is not for the CRES101 clinical trial. I think the financing is for pocket money, engaging CRES101 clinical trial sites, and to allow Ladenburg Thalmann clients to wet their beaks on the Bioasis project. I'm just going by what was stated at the Cresence webinar.  From my notes: Cost of about 6 million (it will be more IMO -- planning fallacy at work), funding most

[JDavenport]

Well, if there is one thing that DrDR is good at, it's dissembling, obfuscation, underestimating shareholders' intelligence, etc etc. She's too cute by half in her statements. Many of them can mean anything. I have a video recording of the webinaire if you want to listen to it again. I keep a record of that stuff because of the ambiguity of her statements. It is a mistake to think

[prophetoffactz]

"I think a financing is not for the CRES101 clinical trial. I think the financing is for pocket money, engaging CRES101 clinical trial sites, and to allow Ladenburg Thalmann clients to wet their beaks on the Bioasis project." Ideally BTI has enough money for 12 months or more or to get to key catalysts; especially in a dramatic risk-on/risk-off market like we've been in or investors

[JDavenport]

Lol, that was an exceptional post, pof. Seldom has so much said so little. All you did was rearrange the words describing the party line. jd